【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.

智通财经06-15

【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.US)两款1类新药获批临床，二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料，这两款产品均为三特异性抗体，为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗，PF-07275315为抗IL-4/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2443295933?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-15 09:39","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2443295933","market":"us","top_or_hot":-1,"title":"【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.","media":"智通财经","content":"<div>\n<p>【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.US)两款1类新药获批临床，二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料，这两款产品均为三特异性抗体，为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗，PF-07275315为抗IL-4/...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-15 09:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=usstock><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.US)两款1类新药获批临床，二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料，这两款产品均为三特异性抗体，为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗，PF-07275315为抗IL-4/...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999013999.USD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2443295933","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443295933","pubTimestamp":1718415541,"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.US)两款1类新药获批临床，二者均拟开发治疗成人中度至重度","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","BK4581":"高盛持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4017":"黄金","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4592":"伊斯兰概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","CDE":"科尔黛伦矿业","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","TSLP":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999002232.USD":"Allianz Global High Payout USD","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4588":"碎股","PFE":"辉瑞"},"translate_title":"[Two new tertiary antibody drugs of Pfizer (PFE.US) have been approved for clinical use in China] Zhitong Finance APP learned that on June 13, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Pfizer (PFE.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLP":1,"PFE":1,"CDE":1},"content_text":"【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.US)两款1类新药获批临床，二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料，这两款产品均为三特异性抗体，为该公司炎症和免疫管线中的新分子实体。其中PF-07264660为抗IL-4/IL-13/IL-33三抗，PF-07275315为抗IL-4/IL-13/TSLP三抗，这两款产品目前在国际范围内均处于2期临床阶段。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443295933"}